Jun Sato

11PUBLICATIONS
54CO-AUTHORS
Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer geneticsCancer therapy (excl. chemotherapy and radiation therapy)Molecular medicine
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|May 18, 2026
Phase I Study of Rogocekib in Patients with Advanced, Relapsed, or Refractory Malignant Solid Tumors.

|Jan 20, 2025
A Phase I, First-In-Human Study of CBA-1205, an Anti-DLK1 Monoclonal Antibody, in Patients With Advanced Solid Tumors.

Yuki Katsuya, Masafumi Ikeda, Takafumi Koyama

|Aug 14, 2024
Phase I Study of Simlukafusp Alfa (FAP-IL2v) with or without Atezolizumab in Japanese Patients with Advanced Solid Tumors.

Takafumi Koyama, Kan Yonemori, Toshio Shimizu

|Nov 02, 2023
Pathogenic Germline Variants in BRCA1/2 and p53 Identified by Real-world Comprehensive Cancer Genome Profiling Tests in Asian Patients.

Tomoyuki Satake, Shunsuke Kondo, Noriko Tanabe

|Jul 12, 2023
Phase Ib/II Study of a Liposomal Formulation of Eribulin (E7389-LF) plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase Ib.

Hanae Ida, Toshio Shimizu, Makoto Nishino

|Sep 09, 2022
First-in-human study of ONO-4578, an antagonist of prostaglandin E2 receptor 4, alone and with nivolumab in solid tumors.

Satoru Iwasa, Takafumi Koyama, Makoto Nishino

Pageof 2

Frequent Collaborators

10 joint publications

Noboru Yamamoto

9 joint publications

Takafumi Koyama

7 joint publications

Kan Yonemori

5 joint publications

Yuki Katsuya